In the past week, RLAY stock has gone down by -4.28%, with a monthly decline of -9.51% and a quarterly plunge of -19.65%. The volatility ratio for the week is 4.91%, and the volatility levels for the last 30 days are 5.31% for Relay Therapeutics Inc. The simple moving average for the last 20 days is -6.74% for RLAY stock, with a simple moving average of -33.12% for the last 200 days.
Is It Worth Investing in Relay Therapeutics Inc. (NASDAQ: RLAY) Right Now?
and a 36-month beta value of 1.38. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The average price predicted for Relay Therapeutics Inc. (RLAY) by analysts is $25.29, which is $16.43 above the current market price. The public float for RLAY is 116.96M, and at present, short sellers hold a 17.00% of that float. On September 15, 2023, the average trading volume of RLAY was 1.02M shares.
RLAY) stock’s latest price update
Relay Therapeutics Inc. (NASDAQ: RLAY)’s stock price has increased by 1.26 compared to its previous closing price of 9.49. However, the company has seen a -4.28% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-08-08 that Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.71 per share a year ago.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Hold.” The predicted price for RLAY in the upcoming period, according to Jefferies is $12.50 based on the research report published on April 20, 2023 of the current year 2023.
RLAY Trading at -14.20% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.88% of loss for the given period.
Volatility was left at 5.31%, however, over the last 30 days, the volatility rate increased by 4.91%, as shares sank -7.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.56% lower at present.
During the last 5 trading sessions, RLAY fell by -4.28%, which changed the moving average for the period of 200-days by -48.39% in comparison to the 20-day moving average, which settled at $10.26. In addition, Relay Therapeutics Inc. saw -35.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Bergstrom Donald A, who sale 2,683 shares at the price of $11.80 back on Jul 28. After this action, Bergstrom Donald A now owns 237,904 shares of Relay Therapeutics Inc., valued at $31,659 using the latest closing price.
Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics Inc., sale 1,693 shares at $11.80 during a trade that took place back on Jul 28, which means that Catinazzo Thomas is holding 146,136 shares at $19,977 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -22516.44 for the present operating margin
- -199.06 for the gross margin
The net margin for Relay Therapeutics Inc. stands at -21036.13. The total capital return value is set at -32.25, while invested capital returns managed to touch -30.22. Equity return is now at value -37.80, with -32.30 for asset returns.
Based on Relay Therapeutics Inc. (RLAY), the company’s capital structure generated 6.08 points at debt to equity in total, while total debt to capital is 5.73. Total debt to assets is 5.25, with long-term debt to equity ratio resting at 5.63. Finally, the long-term debt to capital ratio is 5.30.
When we switch over and look at the enterprise to sales, we see a ratio of 231.29, with the company’s debt to enterprise value settled at 0.08. The receivables turnover for the company is 0.27 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.00.
Conclusion
To sum up, Relay Therapeutics Inc. (RLAY) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
